2019 is upon us, and we are excited to launch our bimonthly newsletter, which is specifically designed to help biotech and pharma companies succeed in their drug development endeavors. The primary objective of our newsletter is to provide guidance on how to address commonly encountered drug development challenges.
Our first edition answers the question “When to conduct a polymorph screen? ”.
If you would like to receive our newsletter with up-to-date drug development insights, industry trends and Ardena news,
please click here to subscribe.
We welcome your feedback and suggestions for future issues.
Navigating you through drug development,